Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Raetz

Showing results (81-90 of 155) with videos related to

Pageof 16
Sort By:
Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.
Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.
Blood|September 28, 2006
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Kirk R Schultz, D Jeanette Pullen, Harland N Sather, et al.
Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Blood|August 9, 2023
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group studyBrent L Wood, Meenakshi Devidas, Ryan J Summers, et al.
Blood Advances|April 15, 2026
Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic LeukemiaRuth W Wang'ondu, John A Kairalla, Mary Shago, et al.
Nature Genetics|February 5, 2013
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemiaJulia A Meyer, Jinhua Wang, Laura E Hogan, et al.
Leukemia|April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Haematologica|December 30, 2017
A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemiaMatthew S Zabriskie, Orlando Antelope, Anupam R Verma, et al.
Pageof 16

Showing results (81-90 of 155) with videos related to

Sort By:
Pageof 16
Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.
Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.
Blood|September 28, 2006
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Kirk R Schultz, D Jeanette Pullen, Harland N Sather, et al.
Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Blood|August 9, 2023
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group studyBrent L Wood, Meenakshi Devidas, Ryan J Summers, et al.
Blood Advances|April 15, 2026
Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-Cell Acute Lymphoblastic LeukemiaRuth W Wang'ondu, John A Kairalla, Mary Shago, et al.
Nature Genetics|February 5, 2013
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemiaJulia A Meyer, Jinhua Wang, Laura E Hogan, et al.
Leukemia|April 13, 2021
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Haematologica|December 30, 2017
A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemiaMatthew S Zabriskie, Orlando Antelope, Anupam R Verma, et al.
Pageof 16